4694-11-5

Usage

Uses

Used in Flavor and Fragrance Industry:
2,2,4,4-Tetramethylcyclopentanone is utilized as a flavor and fragrance ingredient, adding pleasant scents to a range of products such as perfumes, soaps, and lotions. Its mild, sweet odor contributes to the overall sensory experience of these consumer goods.
Used in Industrial Applications:
In addition to its role in the flavor and fragrance industry, 2,2,4,4-Tetramethylcyclopentanone also serves as a solvent in several industrial processes. Its properties make it a valuable component in the formulation and manufacturing of various products, enhancing their performance and quality.

InChI:InChI=1/C9H16O/c1-8(2)5-7(10)9(3,4)6-8/h5-6H2,1-4H3

Upstream product

• 4694-12-6 2,4,4-trimethylcyclopentan-1-one 
• 67522-23-0 1-hydroxy-2,2,4,4-tetramethyl-cyclopentanecarboxylic acid 
• 78-59-1 3,5,5-Trimethylcyclohex-2-en-1-one 
• 25162-95-2 2,2,4,4-Tetramethylhexanedioic acid 
• 63831-53-8 3,5,5-trimethyl-3-(trimethylstannyl)cyclohexanone 
• 2065-76-1 2,6-dibromo-3,3,5,5-tetramethylcyclohexanone 
• 60681-12-1 3,3,5,5-tetramethyl-cyclohexane-1,2-dione 

Downstream Products

• 50876-33-0 1,1,3,3-tetramethyl-cyclopentane 
• 20633-06-1 3,3,5,5-tetramethylcyclopentane-1,2-dione 
• 64637-01-0 2-hydroxy-4,4,6,6-tetramethylcyclohex-2-enone 
• 60681-10-9 4,4,6,6-Tetramethyl-cyclohexane-1,3-dione 
• 60585-45-7 2-Diazo-4,4,6,6-tetramethyl-cyclohexane-1,3-dione 
• 60681-13-2 3-Methoxy-4,4,6,6-tetramethyl-cyclohex-2-enone 
• 38667-10-6 1,1,3,3-Tetramethyl-cyclopenten-⁽⁴⁾ 

Relevant academic research and scientific papers

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Trisubstituted Stannyllithium as a Double Electron Equivalent. Reaction with α,β-Enones

β-Stannyl ketones, easily available by the conjugate addition of (trimethylstannyl)lithium to α,β-enones, produced two types of ketones depending upon the substitution pattern by the treatment with titanium(IV) chloride.All the reactions proceeded through an intermediacy of cyclopropanol derivatives.The reaction involving the carbon skeleton rearrangement is promising as a synthetic method.

THE REACTION OF β-STANNYL CARBONYL COMPOUNDS WITH LEWIS ACIDS

β-Stannyl carbonyl compounds, when treated with Lewis acids, afforded cyclopropane derivatives or ketones, and the reaction was applied to the synthesis of β,γ-enones from α,β-enones.